08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Shooting F-stars

F-star Alpha Ltd. 's deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
07:00 , Jun 5, 2014 |  BC Innovations  |  Strategy

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
07:00 , May 19, 2014 |  BioCentury  |  Finance

Play it again, Celldex

Investors flocked to Celldex Therapeutics Inc. (NASDAQ:CLDX) after the company announced a cancer immunotherapy partnership with Bristol-Myers Squibb Co. (NYSE:BMY). Buysiders may be hoping the narrow nature of the BMS deal means the biotech isn't...
08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

Arbor Pharmaceuticals, Takeda sales and marketing update

Takeda granted Arbor's Arbor Pharmaceuticals Ireland Ltd. subsidiary exclusive rights to commercialize hypertension drugs Edarbi azilsartan medoxomil and Edarbyclor azilsartan medoxomil/chlorthalidone in the U.S. Takeda, which has already launched the products in the U.S., will...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Azor/Sevikar olmesartan/amlodipine regulatory update

FDA issued a drug safety communication warning that hypertension drug olmesartan can cause intestinal problems known as sprue-like enteropathy, which includes symptoms such as severe, chronic diarrhea with substantial weight loss. FDA said it approved...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Daiichi Sankyo, Kowa sales and marketing update

Daiichi and Kowa said the companies terminated their Japanese commercialization partnership for Kowa's cholesterol drug Livalo pitavastatin and Daiichi's hypertension drug Olmetec olmesartan following a review of sales strategy. Effective July 1, the pharmas will...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Azilsartan medoxomil regulatory update

Takeda said that within the first 8 months of this year, it submitted a regulatory application for azilsartan medoxomil in Hong Kong to treat hypertension. The oral angiotensin II type 1 (AT1) receptor blocker (ARB)...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

Edarbyclor azilsartan medoxomil/chlorthalidone regulatory update

Takeda said that within the first 8 months of this year, it submitted regulatory applications for azilsartan medoxomil/chlorthalidone in Taiwan, Thailand and Indonesia to treat hypertension. Takeda markets the fixed-dose combination of azilsartan medoxomil, an...